Autoantibodies and an immune-based rat model of inflammatory bowel disease

World Journal of Gastroenterology

Volumn 19, Issue 43, 2013, Pages 7569-7576

  Esmaily, Hadi ^a   Sanei, Yara ^b   Abdollahi, Mohammad ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Barrier dysfunction; Inflammatory bowel disease rat model; Microbial factor; Pathogenesis

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; NEUTROPHIL CYTOPLASMIC ANTIBODY; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VACCINE;

ARTICLE; AUTOIMMUNITY; ENTERITIS; ENTEROPATHY; GENETIC SUSCEPTIBILITY; HUMAN; HYPOTHESIS; IMMUNE SYSTEM; IMMUNOREGULATION; INFLAMMATION; INTESTINAL BARRIER DYSFUNCTION; INTESTINE MUCOSA PERMEABILITY; NONHUMAN;

BARRIER DYSFUNCTION; INFLAMMATORY BOWEL DISEASE RAT MODEL; MICROBIAL FACTOR; PATHOGENESIS;

ANIMALS; ANTIGENS, BACTERIAL; AUTOANTIBODIES; AUTOIMMUNITY; BACTERIAL TRANSLOCATION; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; INTESTINES; PROGNOSIS; RATS; RISK FACTORS;

EID: 84888094367     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i43.7569     Document Type: Article

References (36)

1. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007; 52: 2015-2021 [PMID: 17404859 DOI: 10.1007/s10620-006-9622-2]
2. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-549 [PMID: 11861611 DOI: 10.1146/annurev.immunol. 20.100301.064816]
3. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008; 14: 401-407 [PMID: 18200662 DOI: 10.3748/wjg.14.401]
4. Weber CR, Turner JR. Inflammatory bowel disease: is it really just another break in the wall? Gut 2007; 56: 6-8 [PMID: 17172583 DOI: 10.1136/gut.2006.104182]
5. Esmaily H, Hosseini-Tabatabaei A, Rahimian R, Khorasani R, Baeeri M, Barazesh-Morgani A, Yasa N, Yassaman Khademi, Mohammad Abdollahi. On the benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells. Cent Eur J Biol 2009; 4: 204-213 [DOI: 10.2478/s11535-008-0053-2]
6. Hosseini-Tabatabaei A, Esmaily H, Rahimian R, Khorasani R, Baeeri M, Barazesh-Morgani A, Sari-Aslani F, Abdollahi M. Benefit of nicorandil on an immunologic murine model of experimental colitis. Cent Eur J Biol 2009; 4: 74-85 [DOI: 10.2478/s11535-008-0047-0]
7. Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004; 50: 81-92 [PMID: 15385082 DOI: 10.1016/j.vascn.2003.12.002]
8. Esmaily H, Vaziri-Bami A, Miroliaee AE, Baeeri M, Abdollahi M. The correlation between NF-κB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam Clin Pharmacol 2011; 25: 723-733 [PMID: 21077947]
9. Gradel KO, Nielsen HL, Schønheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short-and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009; 137: 495-501 [PMID: 19361507 DOI: 10.1053/j.gastro.2009.04.001]
10. Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-351 [PMID: 17368234 DOI: 10.1016/ j.cgh.2006.12.028]
11. Wen Z, Fiocchi C. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol 2004; 11: 195-204 [PMID: 15559364 DOI: 10.1080/17402520400004201]
12. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-533 [PMID: 12876555 DOI: 10.1038/nri1132]
13. Abdolghaffari AH, Nikfar S, Rahimi HR, Abdollahi M. A comprehensive review of antibiotics in clinical trials for inflammatory bowel disease. Int J Pharmacol 2012; 8: 596-613 [DOI: 10.3923/ijp.2012.596.613]
14. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernández-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-2364 [PMID: 7964509 DOI: 10.1084/jem.180.6.2359]
15. Contractor NV, Bassiri H, Reya T, Park AY, Baumgart DC, Wasik MA, Emerson SG, Carding SR. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol 1998; 160: 385-394 [PMID: 9551995]
16. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M. IBD serological panels: facts and perspectives. Inflamm Bowel Dis 2007; 13: 1561-1566 [PMID: 17636565 DOI: 10.1002/ibd.20226]
17. Porter CK, Tribble DR, Aliaga PA, Halvorson HA, Riddle MS. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 2008; 135: 781-786 [PMID: 18640117 DOI: 10.1053/j.gastro.2008.05.081]
18. Nikfar S, Mirfazaelian H, Abdollahi M. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: a systematic review and meta-analysis of placebo-controlled trials. Curr Pharm Des 2010; 16: 3684-3698 [PMID: 21143147]
19. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 41-62 [PMID: 12122743]
20. Fasano A, Baudry B, Pumplin DW, Wasserman SS, Tall BD, Ketley JM, Kaper JB. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA 1991; 88: 5242-5246 [PMID: 2052603 DOI: 10.1073/pnas.88.12.5242]
21. Berkes J, Viswanathan VK, Savkovic SD, Hecht G. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 2003; 52: 439-451 [PMID: 12584232 DOI: 10.1136/gut.52.3.439]
22. Abdolghaffari AH, Baghaei A, Moayer F, Esmaily H, Baeeri M, Monsef-Esfahani HR, Hajiaghaee R, Abdollahi M. On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. Hum Exp Toxicol 2010; 29: 287-295 [PMID: 20144954 DOI: 10.1177/0960327110361754]
23. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14: 4280-4288 [PMID: 18666314 DOI: 10.3748/wjg.14.4280]
24. Rezaie A, Khalaj S, Shabihkhani M, Nikfar S, Zamani MJ, Mohammadirad A, Daryani NE, Abdollahi M. Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients. Ann N Y Acad Sci 2007; 1095: 305-314 [PMID: 17404043 DOI: 10.1196/annals.1397.034]
25. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 2004; 49: 1752-1757 [PMID: 15628697 DOI: 10.1007/ s10620-004-9564-5]
26. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 416-422 [PMID: 16265432 DOI: 10.1038/ncpgasthep0259]
27. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54 [PMID: 11781279 DOI: 10.1053/gast.2002.30294]
28. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999; 11: 648-656 [PMID: 10631550 DOI: 10.1016/S0952-7915(99)00032-1]
29. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004; 84: 282-291 [PMID: 14767487 DOI: 10.1038/labinvest. 3700050]
30. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 1999; 44: 1-13 [PMID: 9952216]
31. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord 2004; 4: 167-174 [PMID: 15580151]
32. Turkcapar N, Toruner M, Soykan I, Aydintug OT, Cetinkaya H, Duzgun N, Ozden A, Duman M. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 2006; 26: 663-668 [PMID: 16136311 DOI: 10.1007/s00296-005-0044-9]
33. Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002; 123: 714-718 [PMID: 12198697 DOI: 10.1053/gast.2002.35396]
34. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006; 6: 244-251 [PMID: 16498453 DOI: 10.1038/nri1784]
35. Nakamura RM, Matsutani M, Barry M. Advances in clinical laboratory tests for inflammatory bowel disease. Clin Chim Acta 2003; 335: 9-20 [PMID: 12927679 DOI: 10.1016/ S0009-8981(03)00286-9]
36. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56: 1394-1403 [PMID: 17456509 DOI: 10.1136/gut.2006.108043]